| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| Targets |
EGFRL858R/T790M/C797S 18 nM (IC50)
|
|---|---|
| ln Vitro |
EGFR-IN-11 (Compound D9; 0.0001-10 µM; 72 hours) exhibits a highly effective inhibitor of HCC827 and H1975 cell lines, with IC50 values of 0.88 nM and 0.20 µM, correspondingly[1]. EGFR-IN-11 (0.01 EGFR-IN-11 1 µM) inhibits the phosphorylation of EGFR in the HCC827, H1975, and A549 cell line in a concentration-dependent manner[1]. Potently inducing apoptosis in HCC827 cells, EGFR-IN-11 (1 µM; 24 h) also causes cell cycle arrests in HCC827 cells[1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Human lung cancer cell lines HCC827 (EGFRDel E746-A750), H1975 (EGFRL858R/T790M) and A549 (EGFRWT); epidermoid carcinoma cell line A431 (EGFRWT) Tested Concentrations: 0.0001, 0.0003, 0.001, 0.003, 0.01, 0.1, 1, 10 µM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibited HCC827 H1975 A549 cells proliferation with IC50s of 0.88±0.09 nM, 0.20±0.01 μM, 2.91 ±0.61 μM, and >10 μM, respectively. Western Blot Analysis[1] Cell Types: HCC827, H1975 and A549 cells Tested Concentrations: 1.00, 0.10 and 0.01 µM for HCC827 cells; 10.00, 1.00 and 0.10 µM for H1975 and A549 cells Incubation Duration: 8 hrs (hours) Experimental Results: Suppressed EGFR phosphorylation in a concentration-dependent manner. EGFR phosphorylation in the HCC827 cell line was more remarkably suppressed than in the H1975 and A549 cell lines. Apoptosis Analysis[1] Cell Types: HCC827 cells Tested Concentrations: 1 µM Incubation Duration: 24 hrs (hours) Experimental Results: The percentages of apoptotic cells is 56.91%. Cell Cycle Analysis[1] Cell Types: HCC827 cells Concen |
| References |
[1]. Lei H, et al. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. Eur J Med Chem. 2019 Nov 16:111888.
|
| Molecular Formula |
C29H35N9O2S
|
|---|---|
| Molecular Weight |
573.71
|
| Exact Mass |
573.26
|
| Elemental Analysis |
C, 60.71; H, 6.15; N, 21.97; O, 5.58; S, 5.59
|
| CAS # |
2463200-44-2
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C=N3)N=C(NC5=CC=CC=C5)N4[C@H]6CN(CC6)S(C7CC7)(=O)=O
|
| InChi Key |
RNEHWYIFHKBZAW-XMMPIXPASA-N
|
| InChi Code |
InChI=1S/C29H35N9O2S/c1-35-15-17-36(18-16-35)23-9-7-22(8-10-23)31-28-30-19-26-27(34-28)38(29(33-26)32-21-5-3-2-4-6-21)24-13-14-37(20-24)41(39,40)25-11-12-25/h2-10,19,24-25H,11-18,20H2,1H3,(H,32,33)(H,30,31,34)/t24-/m1/s1
|
| Chemical Name |
(R)-9-(1-(cyclopropylsulfonyl)pyrrolidin-3-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine
|
| Synonyms |
EGFR-IN-11; RXN00442; RXN-00442; RXN 00442;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (217.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7430 mL | 8.7152 mL | 17.4304 mL | |
| 5 mM | 0.3486 mL | 1.7430 mL | 3.4861 mL | |
| 10 mM | 0.1743 mL | 0.8715 mL | 1.7430 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
